The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Dose-dependent Blockade to Cardiomyocyte Hypertrophy by Histone Deacetylase Inhibitors
Open accessAbstract
Postnatal cardiac myocytes respond to stress signals by hypertrophic growth and activation of a fetal gene program. Recently, we showed that class II histone deacetylases (HDACs) suppress cardiac hypertrophy, and mice lacking the class II HDAC, HDAC9, are sensitized to hypertrophic signals. To further define the roles of HDACs in cardiac hypertrophy, we analyzed the effects of HDAC inhibitors on the responsiveness of primary cardiomyocytes to hypertrophic agonists. Paradoxically, HDAC inhibitors imposed a dose-dependent blockade to hypertrophy and fetal gene activation. We conclude that distinct HDACs play positive or negative roles in the control of cardiomyocyte hypertrophy. HDAC inhibitors are currently being tested in clinical trials as anti-cancer agents. Our results suggest that these inhibitors may also hold promising clinical value as therapeutics for cardiac hypertrophy and heart failure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jenuwein, T., & Allis, C. D. (2001) · Science · doi:10.1126/science.1063127 · Cited by 9,756
Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase
Imai, S.-I., Armstrong, C. M., Kaeberlein, M., & Guarente, L. (2000) · Nature · doi:10.1038/35001622 · Cited by 3,510
Histone deacetylases and cancer: causes and therapies
Marks, P. A., Rifkind, R. A., Richon, V. M., Breslow, R., Miller, T., & Kelly, W. K. (2001) · Nature reviews. Cancer · doi:10.1038/35106079 · Cited by 1,866
Yoshida, M., Kijima, M., Akita, M., & Beppu, T. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)44885-x · Cited by 1,854
Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors
Finnin, M. S., Donigian, J. R., Cohen, A., Richon, V. M., Rifkind, R. A., Marks, P. A., Breslow, R., & Pavletich, N. P. (1999) · Nature · doi:10.1038/43710 · Cited by 1,714
Histone-deacetylase inhibitors: novel drugs for the treatment of cancer
Johnstone, R. W. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd772 · Cited by 1,515
Cardiac Hypertrophy: The Good, the Bad, and the Ugly
Frey, N., & Olson, E. N. (2003) · Annual Review of Physiology · doi:10.1146/annurev.physiol.65.092101.142243 · Cited by 1,449
Self-citationPhylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins
Frye, R. A. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3000 · Cited by 1,409
Histone Deacetylase Inhibitors: Inducers of Differentiation or Apoptosis of Transformed Cells
Marks, P. A., Richon, V. M., & Rifkind, R. A. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.15.1210 · Cited by 1,157
Class II Histone Deacetylases Act as Signal-Responsive Repressors of Cardiac Hypertrophy
Zhang, C. L., McKinsey, T. A., Chang, S., Antos, C. L., Hill, J. A., & Olson, E. N. (2002) · Cell · doi:10.1016/s0092-8674(02)00861-9 · Cited by 973
Self-citation
Cited by
Haberland, M., Montgomery, R. L., & Olson, E. N. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2485 · Cited by 2,526
Self-citationHistone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility
Montgomery, R. L., Davis, C. A., Potthoff, M. J., Haberland, M., Fielitz, J., Qi, X., Hill, J. A., Richardson, J. A., & Olson, E. N. (2007) · Genes & Development · doi:10.1101/gad.1563807 · Cited by 712
Self-citationChang, S., McKinsey, T. A., Zhang, C. L., Richardson, J. A., Hill, J. A., & Olson, E. N. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.19.8467-8476.2004 · Cited by 613
Self-citationVega, R. B., Harrison, B. C., Meadows, E., Roberts, C. R., Papst, P. J., Olson, E. N., & McKinsey, T. A. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.19.8374-8385.2004 · Cited by 511
Self-citationChromatin regulation by Brg1 underlies heart muscle development and disease
Hang, C. T., Yang, J., Han, P., Cheng, H.-L., Shang, C., Ashley, E., Zhou, B., & Chang, C.-P. (2010) · Nature · doi:10.1038/nature09130 · Cited by 470
Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3β activity
Trivedi, C. M., Luo, Y., Yin, Z., Zhang, M., Zhu, W., Wang, T., Floss, T., Goettlicher, M., Noppinger, P. R., Wurst, W., et al. (2007) · Nature Medicine · doi:10.1038/nm1552 · Cited by 468
Control of Cardiac Growth by Histone Acetylation/Deacetylation
Backs, J., & Olson, E. N. (2006) · Circulation Research · doi:10.1161/01.res.0000197782.21444.8f · Cited by 440
Self-citationSizing up the heart: development redux in disease
Olson, E. N., & Schneider, M. D. (2003) · Genes & Development · doi:10.1101/gad.1110103 · Cited by 385
Self-citationSuppression of Class I and II Histone Deacetylases Blunts Pressure-Overload Cardiac Hypertrophy
Kong, Y., Tannous, P., Lu, G., Berenji, K., Rothermel, B. A., Olson, E. N., & Hill, J. A. (2006) · Circulation · doi:10.1161/circulationaha.106.625467 · Cited by 377
Self-citationKee, H. J., Sohn, I. S., Nam, K. I., Park, J. E., Qian, Y. R., Yin, Z., Ahn, Y., Jeong, M. H., Bang, Y.-J., Kim, N., et al. (2006) · Circulation · doi:10.1161/circulationaha.105.559724 · Cited by 368
Maintenance of cardiac energy metabolism by histone deacetylase 3 in mice
Montgomery, R. L., Potthoff, M. J., Haberland, M., Qi, X., Matsuzaki, S., Humphries, K. M., Richardson, J. A., Bassel-Duby, R., & Olson, E. N. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35847 · Cited by 362
Self-citationEpigenetic regulation in cardiovascular disease: mechanisms and advances in clinical trials
Shi, Y., Zhang, H., Huang, S., Yin, L., Wang, F., Luo, P., & Huang, H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01055-2 · Cited by 362
Kook, H., Lepore, J. J., Gitler, A. D., Lu, M. M., Wing-Man Yung, W., Mackay, J., Zhou, R., Ferrari, V., Gruber, P., & Epstein, J. A. (2003) · Journal of Clinical Investigation · doi:10.1172/jci19137 · Cited by 332
Xie, M., Kong, Y., Tan, W., May, H., Battiprolu, P. K., Pedrozo, Z., Wang, Z. V., Morales, C., Luo, X., Cho, G., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.002416 · Cited by 326
Foxo Transcription Factors Blunt Cardiac Hypertrophy by Inhibiting Calcineurin Signaling
Ni, Y. G., Berenji, K., Wang, N., Oh, M., Sachan, N., Dey, A., Cheng, J., Lu, G., Morris, D. J., Castrillon, D. H., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.637124 · Cited by 312
Alcendor, R. R., Kirshenbaum, L. A., Imai, S.-I., Vatner, S. F., & Sadoshima, J. (2004) · Circulation Research · doi:10.1161/01.res.0000147557.75257.ff · Cited by 303
Walsh, D. P., & Chang, Y.-T. (2006) · Chemical Reviews · doi:10.1021/cr0404141 · Cited by 296
Toward transcriptional therapies for the failing heart: chemical screens to modulate genes
McKinsey, T. A., & Olson, E. N. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200524144 · Cited by 288
Self-citationSaleh, H. A., Yousef, M. H., & Abdelnaser, A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.606069 · Cited by 255
Therapeutic potential for HDAC inhibitors in the heart
McKinsey, T. A. (2012) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134712 · Cited by 230
Self-citationTargeting MRTF/SRF in CAP2‐dependent dilated cardiomyopathy delays disease onset
Xiong, Y., Bedi, K., Berritt, S., Attipoe, B. K., Brooks, T. G., Wang, K., Margulies, K. B., & Field, J. (2019) · JCI Insight · doi:10.1172/jci.insight.124629 · Cited by 20
Metadata
- Authors
- Antos, C. L., McKinsey, T. A., Dreitz, M., Hollingsworth, L. M., Zhang, C.-L., Schreiber, K., Rindt, H., Gorczynski, R. J., & Olson, E. N.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2003-08
- Volume
- 278
- Issue
- 31
- Pages
- 28930-28937
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2021860877
- Cited by
- 269
- References
- 59
- FWCI
- 4.40
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.